An excellent, sober presentation in my opinion! Not what some investors may have wanted to hear but it is what it is. It is what Cytodyn wants to say at this time. I'll take it gladly.

I think we just witnessed the presentations that will be made at the various medical conferences noted in one of Cyrus's slide. I think Cyrus's point was that, at these conferences, we do not have many competitors and from them conference participants will hear nothing half as exciting as what we heard today.

Immunotherapy is getting a lot of buzz these days in medical research but the buzz is only really beginning. And Cytodyn and Leronlimab are right at the forefront! Oh, can you hear the buzz!

All those companies that are targeting tumors and pathogens directly or even the mRNA direction are going to find that the strategy of strengthening the immune system is a much more fruitful direction.

The agents of disease (cancer and pathogens) spend a lot of time trying to get around the immune system or to compromise it or even turn it to do work for their progression. A corrected immune system will kick their asses.

And in the worst cases, an immune system aided by a genetically engineered virus that has the body creating Leronlimab constantly is extremely powerful. Most of us have CCR5 receptors in our bodies for good reasons. But if CCR5 receptors become exploited by some disease agent, Sasha's research can permanently block that exploitation.

So, I trust the Cytodyn team and that the buzz will eventually be deafening!